(QSI) QuantumSi - Overview
Sector: Healthcare | Industry: Medical Devices | Exchange: NASDAQ (USA) | Market Cap: 201m USD | Total Return: -43.8% in 12m
Avg Turnover: 4.33M
Qual. Beats: 2
Rev. Trend: 79.8%
Qual. Beats: 0
Warnings
Share dilution 18.7% YoY
Interest Coverage Ratio -12.7 is critical
Beneish M-Score 1.00 > -1.5 - likely earnings manipulation
Altman Z'' -15.00 < 1.0 - financial distress zone
Extended 1w Volatile
Tailwinds
No distinct edge detected
Quantum-Si Inc. (QSI) is a life sciences technology company specializing in next-generation protein sequencing (NGPS). The company utilizes a proprietary semiconductor-based detection platform to achieve single-molecule, amino acid-level resolution. Its commercial portfolio includes the Platinum and Platinum Pro instruments, library preparation kits, specialized reagents, and cloud-based analysis software for automated data visualization.
The company operates within the proteomics sector, a field focused on the large-scale study of proteins to understand cellular functions and disease mechanisms. Unlike genomic sequencing, which is highly standardized, proteomics requires the detection of complex post-translational modifications, creating a high barrier to entry for hardware developers. Quantum-Si follows a razor and blade business model, generating recurring revenue through the sale of consumable sequencing kits required to operate its proprietary hardware.
Investors analyzing the scalability of this sequencing platform may find additional context on ValueRay useful for their diligence. The company is headquartered in Branford, Connecticut, and continues to expand its automated protein analysis workflows for clinical and academic research.
- Platinum instrument adoption and installed base growth drive recurring consumable revenue
- Expansion of protein sequencing library kits increases total addressable market reach
- High cash burn rate and path to profitability influence capital structure
- Competitive pressure from established proteomics platforms impacts long-term market share capture
- Research and development spending levels dictate pace of next-generation product innovation
| Net Income: -103.8m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.45 > 0.02 and ΔFCF/TA -9.61 > 1.0 |
| NWC/Revenue: 6.71k% < 20% (prev 6.66k%; Δ 51.20% < -1%) |
| CFO/TA -0.44 > 3% & CFO -94.2m > Net Income -103.8m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 12.60 > 1.5 & < 3 |
| Outstanding Shares: last quarter (216.5m) vs 12m ago 18.74% < -2% |
| Gross Margin: 40.01% > 18% (prev 0.53%; Δ 3.95k% > 0.5%) |
| Asset Turnover: 0.76% > 50% (prev 1.27%; Δ -0.51% > 0%) |
| Interest Coverage Ratio: -12.68 > 6 (EBITDA TTM -91.5m / Interest Expense TTM 7.59m) |
| A: 0.58 (Total Current Assets 135.0m - Total Current Liabilities 10.7m) / Total Assets 213.3m |
| B: -3.37 (Retained Earnings -719.7m / Total Assets 213.3m) |
| C: -0.40 (EBIT TTM -96.3m / Avg Total Assets 242.3m) |
| D: -57.13 (Book Value of Equity -720.0m / Total Liabilities 12.6m) |
| Altman-Z'' = -69.83 = D |
| DSRI: 0.37 (Receivables 203k/1.03m, Revenue 1.85m/3.44m) |
| GMI: 1.32 (GM 40.01% / 52.77%) |
| AQI: 99.52 (AQ_t 0.30 / AQ_t-1 0.00) |
| SGI: 0.54 (Revenue 1.85m / 3.44m) |
| TATA: -0.05 (NI -103.8m - CFO -94.2m) / TA 213.3m) |
| Beneish M = 54.79 (Cap -4..+1) = D |
As of May 27, 2026, the stock is trading at USD 1.08 with a total of 7,427,475 shares traded.
Over the past week, the price has changed by +26.46%,
over one month by +20.00%,
over three months by +6.93% and
over the past year by -43.75%.
QuantumSi has received a consensus analysts rating of 4.00. Therefore, it is recommended to buy QSI.
- StrongBuy: 1
- Buy: 1
- Hold: 1
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 2.5 | 131.5% |
P/S = 108.4215
P/B = 0.9518
Revenue TTM = 1.85m USD
EBIT TTM = -96.3m USD
EBITDA TTM = -91.5m USD
Long Term Debt = 1.87m USD (estimated: total debt 3.71m - short term 1.84m)
Short Term Debt = 1.84m USD (from shortTermDebt, last quarter)
Debt = 3.71m USD (from shortLongTermDebtTotal, last quarter) (leases 3.71m already included)
Net Debt = -123.6m USD (calculated: Debt 3.71m - CCE 127.3m)
Enterprise Value = 77.2m USD (200.8m + Debt 3.71m - CCE 127.3m)
Interest Coverage Ratio = -12.68 (Ebit TTM -96.3m / Interest Expense TTM 7.59m)
EV/FCF = -0.81x (Enterprise Value 77.2m / FCF TTM -95.7m)
FCF Yield = -124.0% (FCF TTM -95.7m / Enterprise Value 77.2m)
FCF Margin = -5.17k% (FCF TTM -95.7m / Revenue TTM 1.85m)
Net Margin = -5.61k% (Net Income TTM -103.8m / Revenue TTM 1.85m)
Gross Margin = 40.01% ((Revenue TTM 1.85m - Cost of Revenue TTM 1.11m) / Revenue TTM)
Gross Margin QoQ = 28.68% (prev 27.05%)
Tobins Q-Ratio = 0.36 (Enterprise Value 77.2m / Total Assets 213.3m)
Interest Expense / Debt = 204.7% (Interest Expense 7.59m / Debt 3.71m)
Taxrate = 21.0% (US default 21%)
NOPAT = -76.1m (EBIT -96.3m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 12.60 (Total Current Assets 135.0m / Total Current Liabilities 10.7m)
Debt / Equity = 0.02 (Debt 3.71m / totalStockholderEquity, last quarter 200.7m)
Debt / EBITDA = 1.35 (negative EBITDA) (Net Debt -123.6m / EBITDA -91.5m)
Debt / FCF = 1.29 (negative FCF - burning cash) (Net Debt -123.6m / FCF TTM -95.7m)
Total Stockholder Equity = 219.3m (last 4 quarters mean from totalStockholderEquity)
RoA = -42.85% (Net Income -103.8m / Total Assets 213.3m)
RoE = -11.06% (Net Income TTM -103.8m / Total Stockholder Equity 938.9m)
RoCE = -10.24% (EBIT -96.3m / Capital Employed (Equity 938.9m + L.T.Debt 1.87m))
RoIC = -37.21% (negative operating profit) (NOPAT -76.1m / Invested Capital 204.5m)
WACC = 13.47% (E(200.8m)/V(204.5m) * Re(13.72%) + (debt cost/tax rate unavailable))
Discount Rate = 13.72% (= CAPM, Blume Beta Adj.) -> capped to 13.17%
Shares (quarterly) Correlation: 95.56 | Cagr: 20.77%
[DCF] Fair Price = unknown (Cash Flow -95.7m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.84 | # QB: 2
Revenue Correlation: 79.83 | Revenue CAGR: 79.02% | SUE: -0.22 | # QB: 0
EPS current Quarter (2026-06-30): EPS=-0.10 | Chg30d=N/A | Revisions=+20% | Analysts=1
EPS next Quarter (2026-09-30): EPS=-0.11 | Chg30d=+0.00% | Revisions=-20% | Analysts=1
EPS current Year (2026-12-31): EPS=-0.40 | Chg30d=+4.76% | Revisions=+20% | GrowthEPS=-4.7% | GrowthRev=-57.6%
EPS next Year (2027-12-31): EPS=-0.36 | Chg30d=N/A | Revisions=+20% | GrowthEPS=+10.0% | GrowthRev=+834.7%